Bluebird Bio Stock News

bluebird bio, Inc. (NASDAQ:BLUE)s share price gapped up prior to trading on Monday . The stock had previously closed at $10.70, but opened at $11.43. bluebird bio shares last traded at $10.87, with a volume of 11,650 shares traded. BLUE has been the subject of several recent analyst reports. Canaccord Genuity decreased their target price []

Gene Therapy Market Report 2021-2028 includes a comprehensive analysis of the present Market. The report starts with the basic Gene Therapy industry overview and then goes into each and every detail. Gene Therapy Market Report contains in depth information major manufacturers,

bluebird (BLUE) application seeking approval for beti-cel for thalassemia gets priority review in the United States.

Data Bridge Market research released a new market study on Advanced therapy medicinal products with 100+ market data Tables, Pie Chart, Graphs & Figures spread through Pages and easy to understand detailed analysis In Advanced therapy medicinal products research

The trading price of bluebird bio Inc. (NASDAQ:BLUE) closed lower on Friday, November 19, closing at $10.70, -1.92% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Economy

The FDA has accepted Bluebird bio Inc''s (NASDAQ: BLUE ) marketing application for betibeglogene autotemcel (beti-cel) for -thalassemia. The agency has granted priority review for Beti-cel, gene therapy for -thalassemia across all genotypes who require regular red blood cell transfusions. If approved, beti-cel will be the first one-time treatment that addresses Full story available on Benzinga.com

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BLUE--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for betibeglogene autotemcel (beti-cel) for priority review. Beti-cel is a potentially transformative gene therapy for adult, adolescent and pediatric patients with -thalassemia across all genotypes who require regular red blood cell (RBC) transfusions. If approved, beti-cel will be the first one-time treatmen

The FDA has accepted Bluebird bio Inc's (NASDAQ: BLUE) marketing application for betibeglogene autotemcel (beti-cel) for β-thalassemia. The agency has granted priority review for Beti-cel, gene th

The companies are collaborating on a potential blockbuster.

Charles Schwab Investment Management Inc. increased its position in shares of bluebird bio, Inc. (NASDAQ:BLUE) by 46.5% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 451,679 shares of the biotechnology companys stock after purchasing an additional 143,294 shares during the period. Charles []

bluebird bio (NASDAQ:BLUE) had its price target decreased by BMO Capital Markets from $21.00 to $13.00 in a research note issued to investors on Friday morning, The Fly reports. BMO Capital Markets currently has a market perform rating on the biotechnology companys stock. Other analysts also recently issued reports about the company. Royal Bank of []

Two analysts downgraded the biotech stock.

bluebird (BLUE) reports wider-than-expected loss for third-quarter 2021. It also misses revenue estimates.